Fundraising FoxSectoral Asset Management
Institutional investorMontreal · Series B–Late Stage · 8 people tracked
Find your way into Sectoral Asset Management
Sign up to see every warm intro you have to Sectoral Asset Management
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Sectoral Asset Management team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Sectoral's venture arm invests in innovative healthcare companies through its late-stage NEMO family of funds, active since 2008 across North America and Europe. A newer fund, Fonds Medtech Ventures (2023), targets Canadian medtech companies. The team supports portfolio companies with capital and operational expertise to help bring new therapeutics and medical devices to patients worldwide. Its philosophy holds that strong financial returns can align with lasting societal benefits through improved health and well-being.
Source: firm website, verified Sep 29, 2026.
Team · 8 people
from public directories
What they invest in
from 13 of 14 portfolio companiesHealthtech ×10Medical Devices ×9Biotech ×7Hardware ×4Digital Health ×3Deep Tech ×1Wellness & Fitness ×1
HQs:United States×11
Investments · 14 tracked
founders shown can be your intro pathBy year:2026 · 22025 · 12024 · 22023 · 22022 · 12021 · 12020 · 12018 · 212 dated
Apnimed develops investigational oral pharmaceutical therapies for obstructive sleep apnea (OSA), including its lead clinical candidate AD109, a neuromuscular approach intended to treat undertreated and untreated OSA patients.
BiotechDigital HealthHealthtechCambridge, US
Lawrence G. Miller(Executive Officer, Director)inDennis Molnar(Executive Officer)inBarry Wohl(Chief Business Officer)inKetan Mehta(Head of Product and Engineering, Connected Wearables)Ron Farquhar(Director)Gerald Chan(Director)
Co-investorsAlpha Wave GlobalHEALTHCARE ROYALTY PARTNERSMorningside Group
Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.
BiotechMedical DevicesLa Jolla, US
Zachary D. Hornby(Executive Officer, Director)inRobert Doebele(Chief Medical Officer)inChristian Hassig(Chief Scientific Officer)Jessica Oien(Chief Legal Officer and Corporate Secretary)in
BoardBenjamin Cravatt, Ph.D.(Director)Kristina Burow(Director)in
Co-investorsARCH Venture PartnersNextech InvestRA CapitalWellington ManagementAlexandriaCity Hill Ventures+3 more
Contineum is a biopharmaceutical company developing small molecule drug candidates to treat inflammatory and fibrotic diseases by modulating critical disease pathways.
BiotechHealthtech
Carmine Stengone(President and Chief Executive Officer)inPeter T. Slover(Chief Financial Officer)inDaniel S. Lorrain(Chief Scientific Officer)inTimothy R. Watkins(Chief Medical Officer and Head of Development)in
Co-investorsHadean VenturesRed Tree VentureSamsara BioCapitalCasdin CapitalFranklin TempletonJJDC+1 more
Developing therapeutic peptides targeting rare endocrine diseases (past investment).
Co-investorsAndera PartnersATEM Capital FundCTI Life Sciences Fund L.P.EQT Life SciencesKurma PartnersOctalfa+4 more
BiotechSan Leandro, US
Steve Abella(Chief Medical Officer)inGraeme Currie(Chief Operating Officer)inStephen W. Lau(President, Chief Executive Officer, and Treasurer)inKenneth Schwartz(Executive Officer)inEric Yuen(Executive Officer)inMarten Steen(Director)in
Co-investorsEQT Life SciencesHealthCapInkefSofinnova VenturesYsios Capital
CurvaFix develops the CurvaFix Low Profile intramedullary nailing system, curved implants for surgical stabilization of pelvic fractures.
HardwareHealthtechMedical DevicesBellevue, US
Jeffrey Poole(Executive Officer)Mark Foster(Executive Officer, Director)inSteven Dimmer(Executive Officer, Director, Promoter)Dong-Gun Kim(Director)
BoardEric Fritz(Director)inJack Tanaka(Director)in
Co-investorsAlliance of AngelsArieal Southeast Angel PartnersRockies Venture ClubSPRINGROCK VENTURESSwan Venture FundKeiretsu Capital+2 more
LENZ Therapeutics is a pharmaceutical company developing and commercializing VIZZ™, an FDA-approved aceclidine-based eye drop for treating presbyopia, a vision condition affecting over 128 million people in the US.
BiotechHealthtechMedical DevicesSan Diego, US
James McCollum(Co-founder, Board Member)Eef SchimmelpenninkinEvert Schimmelpennink(President and CEO)
Co-investorsAlpha Wave GlobalRA CapitalRaptor GroupRTW Investments L.P.Versant Ventures
Magnolia Medical develops diagnostic devices to reduce blood culture contamination and false-positive sepsis test results for hospitals and healthcare systems.
HardwareHealthtechMedical DevicesSeattle, US
Gregory J Bullington(Executive Officer, Director)Richard Patton(Co-founder)
BoardPaul Meister(Director)
Co-investorsEvidity Health CapitalLauder PartnersMarram VenturesRhapsody Venture PartnersVivo CapitalHealthQuest Capital+3 more
Neuros Medical develops the Altius Direct Electrical Nerve Stimulation System, an FDA-approved implantable device that delivers patient-controlled electrical stimulation to treat chronic post-amputation pain in adult lower limb amputees.
BiotechHealthtechMedical DevicesAliso Viejo, US
David Veino(President and CEO)Zach Stassen(Chief Financial Officer)Robert J. Centa(Chief Financial Officer)Jon J. Snyder(Director, President, Secretary and CEO)in
BoardJoyce Erony(Director)inWilliam Harrington(Director)in
Co-investorsAmzak HealthAPERTURE Venture PartnersCWRU Technology VenturesiSelect FundJobsOhio VenturesJumpstart Ventures+5 more
Noctrix Health develops clinically validated wearable therapeutics for managing chronic neurological disorders, with its first product Nidra receiving FDA De Novo authorization and dedicated CMS HCPCS codes.
Digital HealthMedical DevicesWellness & FitnessPleasanton, US
Shri Raghunathan(Founder)inShriram Raghunathan(Executive Officer, Director)
BoardChau Khuong(Director)inAllan May(Director)Mudit Jain(Director)inTracy Pappas(Director)in
Co-investorsAngelini VenturesBlue Venture FundsJoyance PartnersOrbiMedTreo Ventures, LlcZühlke Ventures+2 more
Phagenesis develops targeted pharyngeal electrical stimulation technology to treat neurogenic dysphagia by restoring neural pathways for safe swallowing.
Deep TechDigital HealthHealthtechMedical Devices
Co-investorsAphelion CapitalInnvotec Ltd.Northern GritstoneEQT Life Sciences
Route 92 Medical develops neurointervention catheter systems and devices aimed at improving outcomes for neurovascular patients, including stroke treatment.
BiotechHardwareHealthtechMedical DevicesSan Mateo, US
Dr. Chou(Founder & Chief Executive Officer)Cindy Lynch(Executive Officer)inDr. Joey English(Chief Medical Officer)Tony Chou(Founder)in
BoardJack Lasersohn(Director)inTamir Meiri(Director)
Co-investorsNovo HoldingsThe Vertical GroupNorwest Venture PartnersRunway Growth CapitalUS Venture PartnersSofinnova Ventures+1 more
Shockwave Medical develops intravascular lithotripsy (IVL) catheter systems used to treat calcified cardiovascular disease, marketed to interventional cardiologists and vascular specialists.
HardwareHealthtechMedical DevicesFremont, US
Daniel Hawkins(Executive Officer, Director)inTodd J. Brinton(Director)inIsaac(President)
BoardJay Watkins(Director)inAntoine Papiernik(Director)inFrederic H. Moll(Director)
Co-investorsSofinnova PartnersSonder CapitalVenrock
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Exits · 3
3 IPOsApnimedNASDAQ: APMDBoundless BioNASDAQ: BOLDContineum TherapeuticsNASDAQ: CTNM
Portfolio news
latest coverage across their companies
Contineum Therapeutics · stocktitan.net · Aug 25, 2026
Apnimed · forbes.com · Jul 31, 2026
Noctrix Health · finsmes.com · Sep 2, 2025
Neuros Medical · finsmes.com · Jul 9, 2025
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Contineum Therapeutics | 4.1% | $16.00 | Apr 2024 | $15.2M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Sectoral Asset Management made?
- Sectoral Asset Management has 14 tracked investments, 3 of which have exited, including 3 dated in the last 24 months.
- What stage does Sectoral Asset Management invest at?
- Sectoral Asset Management invests at the Series B, Late Stage stages.
- What sectors does Sectoral Asset Management focus on?
- Sectoral Asset Management focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Sectoral Asset Management located?
- Sectoral Asset Management is headquartered in Montreal, CA.
Images
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Menlo Ventures is an early-stage venture capital firm backing transformative technology companies, with a strong current emphasis on artificial intelligence across enterprise, healthcare, and consumer markets.
Norwest is a venture capital and growth equity investment firm that has backed over 700 companies across technology, consumer, and healthcare over its 65-year history.
Venrock is a venture capital firm investing across technology and healthcare, backing companies in fintech, developer infrastructure, life sciences, therapeutics, semiconductors, and consumer products.